Novel Neuroscience Candidate
Multiple System Atrophy (MSA)
Key Facts
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is executing a successful 'Pivot to Growth' strategy, transitioning from a generics-centric model to an innovation-driven biopharmaceutical company. This shift has yielded three consecutive years of revenue growth, driven by its specialty portfolio in CNS disorders and a burgeoning biosimilars pipeline. The company's integrated model, spanning complex generics, API manufacturing, and novel drug development, provides a durable competitive moat and positions it to address both affordability and unmet medical needs globally.
View full company profileAbout Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is executing a successful 'Pivot to Growth' strategy, transitioning from a generics-centric model to an innovation-driven biopharmaceutical company. This shift has yielded three consecutive years of revenue growth, driven by its specialty portfolio in CNS disorders and a burgeoning biosimilars pipeline. The company's integrated model, spanning complex generics, API manufacturing, and novel drug development, provides a durable competitive moat and positions it to address both affordability and unmet medical needs globally.
View full company profileTherapeutic Areas
Other Multiple System Atrophy (MSA) Drugs
| Drug | Company | Phase |
|---|---|---|
| HB-adMSCs for Multiple System Atrophy | Hope Biosciences | Phase 1/2 |
| Anti-alpha-synuclein program for MSA (acquired by AC Immune) | AFFiRiS | Phase 1 |
| MSA Program | ProMIS Neurosciences | Preclinical |
| anle138b | Modag | Phase 1/2 |
| Anti-alpha-synuclein Oligomer mAb | BioArctic AB | Discovery |
| ATH434 | Alterity Therapeutics | Phase 2 |